Skip to content

Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event

Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04872075
Acronym
SPRING
Enrollment
6678
Registered
2021-05-04
Start date
2021-05-26
Completion date
2021-06-13
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Sars-Cov-2, Covid-19, Screening, Concert, Closed area, Standing configuration

Brief summary

The objective is to demonstrate if there is no increase in the risk of Sars-Cov-2 salivary carriage 7 days after a concert in the group participating in the event compared to a non participating group who stayed at home. The hypothesis is that a systematic screening of Sars-Cov-2 within the 3 days before the event allows to control the risk of transmission and prevent cluster of transmission during the concert.

Detailed description

Before inclusion, the participants will be able to pre-register to the event via a website. They will get an appointment for an inclusion visit at the Accor Arena (Paris Bercy, France). During 3 days (from D-3 to D-1), participants with a registration will come to the Accor Arena to have a rapid Sars-Cov-2 antigen test (results in 15 min). If the test is positive, the participant will be contacted and managed by the medical team in charge of the national strategy for positives cases. People with a negative test will be included and randomized : * Two kits with tube for collecting saliva samples (for D0 and D7) will be given to each participant at this visit * People randomized in the experimental group will receive their concert ticket at a later date. * At Day 0, people randomized in the experimental group, will come to the Accor Arena with their ticket to participate in the concert. At the entrance, they should give their D0 saliva sampling kit. The people randomized in the control group will stay at home and will send their D0 saliva sample by post mail. * At Day 7 (±1 day) all the participants must return their D7 saliva sampling kit via post mail

Interventions

OTHERConcert

People attending a concert in a closed area, with a mask

DIAGNOSTIC_TESTRapid nasopharyngeal antigen test for Sars-Cov-2

A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility

DIAGNOSTIC_TESTSaliva Sample

Saliva samples sent by participant at Day0 and Day7

Sponsors

PRODISS
CollaboratorUNKNOWN
WEEZEVENT
CollaboratorUNKNOWN
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* aged between 18 and 45 years old * lack of symptoms or no contact with people with Covid-19 in the last two weeks * negative antigenic test to Covid-19 in the 3 days before the experiment * people who declared to have no risk factor to severe form of Covid-19 * people who declared not to live in the same place as someone with these risk factors * people residing in Ile-de-France area

Exclusion criteria

* positive test to Sars-Cov-2 within 3 days before the concert * people with clinical signs suggesting infectious respiratory disease * people with severe Covid-19 risk factor * people living with someone having severe covid-19 risk factor * not affiliated to social security * people who cannot remain standing for the time of the experimentation (about 5 hours) * person under tutorship or curatorship * pregnant women or not having effective contraception method * breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with a positive salivary RT-PCR at day 7 after the date of the concert7 days after the concert (-1/+8 days)Prove the lack of increase of salivary carriage risk of SARS-CoV-2 on day 7 in participants present at the concert (experimental group) compared to non-participants at the event (control group)

Secondary

MeasureTime frameDescription
Number of participants in each group with a positive salivary RT-PCR the day of the concertThe day of the concertEvaluation of the salivary carriage on day 0 (the concert day) despite a negative test within 3 days before the event and the conversion rate of salivary carriage between D0 and D7
Molecular analysis of transmission clusters7 days after the concert (-1/+8 days)Comparison of the sequence of complete viral genome in participant with a positive test at day 7
Average percentage of participants wearing their mask adequately for the duration of eventThe day of the concertEstimate the overall compliance of the mask wearing by the participants during the duration of the event (covering nose and mouth)
Percentage of adequate mask wearing among participants according to location and timeThe day of the concertIdentify the circumstances (place, time) of failure of accurate mask wearing by the participants
Percentage of participants who downloaded and / or used the TousAntiCovid application at the time of inclusionThe day of the concertEstimate the feasibility and acceptability of using the Tousanticovid application

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026